Identification of novel candidate biomarkers and efficacious small molecule drugs for pancreatic adenocarcinoma based on comprehensive bioinformatics technology

CURRENT STATUS: POSTED

Jie Yang
Shandong Provincial Hospital

Peng Wang
The first affiliated hospital of Shandong first medical university

Yuan-Yuan Li
The first affiliated hospital of Shandong first medical university

qyliyuanyuan@163.com Corresponding Author
ORCID: https://orcid.org/0000-0002-1864-6542

DOI: 10.21203/rs.3.rs-17133/v1

SUBJECT AREAS
Cancer Biology

KEYWORDS
pancreatic adenocarcinoma (PAAD), biomarker, weighted co-expression network analysis (WGCNA), Connectivity Map (CMap), small molecule drug
Abstract
Background: Pancreatic adenocarcinoma (PAAD) is considered as one of most serious solid tumors with high mortality as well as incidence. We performed this present study to screen out novel biomarkers and potential efficacious small drugs in PAAD using integrated bioinformatics analyses. Methods: Expression profiles derived from TCGA and GTEx datasets were integrated by following bioinformatics methods: DEGs analysis, WGCNA, KEGG and GO enrichment analyses. Kaplan-Meier method was conducted to assess the prognostic performance of genes, and the predictive value of identified genes was determined by the ROC analysis. CMap analysis was utilized to identify the related small molecule drugs in PAAD. Results: A total of 4777 DEGs containing 2536 up-regulated and 2241 down-regulated genes were identified. WGCNA identified six modules that were related with clinical characteristics, and functional enrichment analyses showed that all genes of blue module were enriched in EMT, PI3K/Akt signaling pathway and other important biological processes and pathways. Moreover, three genes ( ITGB1 , ITGB5 , and OSMR ) of blue module were determined as key genes with higher expression levels and significant prognostic value. ROC analysis revealed that these three genes had excellent diagnostic efficiency for PAAD. These three key genes were highly regulated in PAAD tissues compared with normal controls. A panel of small molecule drugs including thapsigargin, viomycin, adiphenine, and CP-690334-01 were screened out to treat PAAD. Conclusion: In conclusion, our findings identified three key genes implicated in PAAD and screened out several potential small drugs to treat it, which may shed novel insights into the development of PAAD and its treatment.

Background
Pancreatic adenocarcinoma (PAAD) is the seventh most common malignancy worldwide[1]. Statistical data showed that there was about 458, 918 new cases and 432,242 cancer deaths in 2018, accounting for 2.5% of all new cases and 4.5% of total deaths, and is estimated to rise to a higher ranking owing to the increasing morbidity and mortality[2]. PAAD is characterized by the propensities of un-time diagnosis, easy metastasis, and resistance for current chemotherapeutic treatments[3].
Due to these features, PAAD has a low five-year survival rate, about less than 10%[4]. Therefore, it is of great importance to understand the potential molecular mechanisms implicated in the development of PAAD and thereby identifying promising biomarkers and novel therapeutic drugs. PAAD is a type of most serious solid tumors with highly complexity in human cancers[5]. Thus, the regulation of molecular mechanisms during the process of tumorigenesis should be identified as the most key factors associated with the PAAD progression. Recently, on the basis of big integrated data and bioinformatics, the promising key genes related with cancer development and prognosis can be identified with the widespread popularity of gene chips and the rapid development of high-throughput sequencing technology. Potential hub genes linked with the pathogenesis and outcome of PAAD were screened out using bioinformatics meta-analysis based on the GEO and TCGA databases[1]. Wu et al. identified a nine-gene signature and established a prognostic nomogram used to predict the prognoses of PAAD patients[6]. A total of 240 differentially expressed genes (DEGs) were identified between normal tissues and early-stage tumor tissues in PAAD[7]. However, DEGs are various in different investigations with a few of same genes. Weighted gene co-expression network analysis (WGCNA) is proposed as a systematic biological methodology which was utilized to construct the co-expression networks of key genes and inquire the association of different sets of genes, within sets of genes and clinicopathological characteristics. It provides an effective functional interpretation tool for identification of candidate key genes, sheds novel insights for cancer treatments, and has been employed in multiple cancers, such as stomach adenocarcinoma[8], clear cell renal cell carcinoma[9], and non-small-cell lung cancer[10]. Furthermore, five hub miRNAs have been identified as potential diagnostic and prognostic candidates for pancreatic ductal adenocarcinoma[11]. Herein, in this present study, we established a co-expression network using DEGs correlated with PAAD development through accessing to TCGA and Oncomine databases, and determined the important gene sets that closely linked with PAAD using WGCNA. KEGG and GO enrichment analyses were performed to better explore the functional roles of identified DEGs. Overall survival of these DEGs was detected using Kaplan-Meier method and small molecule drugs related to them were screened out for the potential use in the treatment of PAAD.
Materials And Methods
Data collection of gene expression profiles
To identify the DEGs in PAAD, the RNA-Seq data of PAAD were downloaded from the TCGA database (https://cancergenome.nih.gov/), which contains 178 tumor samples and 4 normal samples. Due to there were only 4 normal samples of adjacent tissue samples, we integrated the RNA-Seq data of 171 normal pancreas specimens from the Genotype-Tissue Expression (GTEx) dataset (https://gtexportal.org/).

Data preprocessing and screening for DEGs
The “limma” package of R software was used to standardize and transform the RNA-Seq data and screen the DEGs between PAAD samples and normal pancreas tissue specimens[12]. |logFC (fold change)| > 1 and false discovery rate (FDR) < 0.05 were considered as the threshold for DEGs screening.

Weighted co-expression network analysis
As previously mentioned, weight gene co-expression network was established by “WGCNA” R package[13]. The input data of WGCNA establishment consists of 4777 DEGs that we had obtained and 176 PAAD samples with pathological staging. At first, clustering the samples and selecting a soft threshold value β based on the standard scale-free networks. Second, the adjacencies among all filtered genes were determined using the power adjacent function to Pearson correlation matrix and then transformed these data into topological overlap matrixs (TOMs). Average linkage hierarchical clustering was performed after calculating the dissimilarity (1-TOM). Finally, in order to further analyze the module, the dissimilarity of module eigengenes was calculated and modules with highly similarity were merged together as the cut-off value of 5.

KEGG and GO enrichment analyses
The biological functions of the genes in blue module were predicted using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses on the basis of the on-line platform of Database for Annotation, Visualization, and Integrated Discovery (DAVID) (http://david.abcc.ncifcrf.gov/). Adjusted P < 0.05 was regarded as the cut-off criteria.

Validation of key genes
To further investigate the possible roles of module genes in the incidence and progression of PAAD,
we conducted Kaplan-Meier analysis on the genes of PI3K/Akt signaling pathway with the most abundant genes in blue module to screen the key genes that have significant prognostic significance in PAAD. The clinical specimens were derived from TCGA database. The receiver operating characteristic (ROC) curve was plotted to compare the sensitivity and specificity of key genes we obtained. The data from Oncomine datasets were utilized to verify the significant difference of identified key genes.

Analysis and identification of DEmiRs
Identification of DEmiRs was performed using the miR-Seq expression profiles that were derived from TCGA (a total of 182 samples including 178 tumor samples and 4 normal specimens). The specific steps were the same as the screening of DEGs, as above described. TargetScan website was used to predict the targeted miRs of key genes.

Identification of potential small molecules
The Connectivity Map (CMap, http://www.broadinstitute.org/cmap/) was employed to screen the potential small molecule drugs that were closely correlated with indicated disease[14]. The DEGs that we identified were contrasted with those genes related with the small molecule drugs treatment in CMap database to screen the potential small molecule drugs linked with DEGs. The range of connectivity value is from −1 to 1: the positive value represents that the small drug can activate the PAAD cells, while negative value represents that these small molecules can be used to reverse the status of PAAD cells.

Results
Screening of DEGs in PAAD
After integrated bioinformatics analyses for TCGA-PAAD and GTEx datasets, a total of 4777 protein-coding genes were found to be differentially expressed with the threshold of |logFC| > 1 and FDR < 0.05. The volcano plot of DEGs in PAAD was presented in Fig. 1. Among these DEGs, 2536 DEGs were up-regulated and 2241 DEGs were down-regulated.

Weighted co-expression network establishment and key modules identification
The 4777 DEGs and 176 PAAD samples with the data of pathological stage and grade were enrolled to construct the WGCNA. Then constructed phylogenetic tree and removed outliers, finally retained 162 samples. After assessing the quality of expression matrix of TCGA and GTEx, “WGCNA” package was
used in R. The value of $\beta = 9$ was chosen to ensure the scale-free network. Next, we set MEDissThres as 5 to merge similar modules and finally identified a total of 12 modules (Fig. 2). Black module included 127 genes, blue module included 553 genes, brown module included 131 genes, green module included 215 genes, green-yellow module included 58 genes, grey module included 2142 genes, magenta module included 106 genes, pink module included 123 genes, purple module included 89 genes, red module included 177 genes, tan module included 42 genes, turquoise module included 562 genes, and yellow module included 249 genes. Genes contained in grey module were identified as not co-expressed and deleted in the further analyses.

Interaction relationship among modules and identification of pivotal modules

The interaction relationship of 12 modules was analyzed using the network heatmap (Fig. 3A). This analysis revealed that every module was independent of each other, which suggested that these 12 modules posed high-scale independence degree and significant independence of genes expression in every module. Afterwards, correlation analysis was implemented between each module and clinical features and the findings indicated that tan and red modules were significantly correlated with the Nude (N) stage of PAAD (Fig. 3B and 3C); yellow, blue and purple modules were remarkably associated with PAAD tumor Stage (Fig. 3D-F); the one that related to Tumor (T) stage was green-yellow (Fig. 3G).

Enrichment analyses of blue module

On the basis of the correlation between identified modules and clinicopathological characteristics, we performed functional enrichment analyses to investigate the biological functions of DEGs that were included in the above mentioned modules (Fig. 3B-G). The results of enrichment analyses revealed that many important biological processes and pathways were enriched in blue module. In Fig. 4A, Go analysis showed that DEGs of the blue module were mainly related with cell-substrate adhesion, cellular response to growth factor stimulus, epithelial to mesenchymal transition (EMT) and cell migration. Furthermore, KEGG enrichment analysis disclosed that these DEGs were significantly associated with ECM-receptor interaction, PI3K/Akt signaling pathway, TGF-β signaling pathway, Hippo signaling pathway and so on (Fig. 4B).

Key genes identification and validation
Based on the results of KEGG enrichment analysis in blue module, we found that the most genes were enriched in PI3K/Akt signaling pathway (Fig. 4B). To identify the key genes, Kaplan-Meier method was performed to plot the survival curves of these genes for prognostic significance assessment and a total of three genes (ITGB1, ITGB5, and OSMR) were observed to be significantly associated with prognosis of PAAD patients. As shown in Fig. 5A-C, high expression of ITGB1, ITGB5, and OSMR induced poorer outcomes of patients with PAAD, while down-regulation of them resulted in a higher survival rate (P < 0.05). Similarly, ITGB1, ITGB5, and OSMR were also negatively associated with the disease free survival of PAAD patients (Fig. 5D-F, P < 0.05). Furthermore, the expression levels of these three genes were remarkably increased in PAAD tissue samples in contrast to normal pancreas specimens (Fig. 5G-I, P < 0.0001). In addition, based on the TCGA database, ROC curves were plotted to examine the diagnostic effects of ITGB1, ITGB5, and OSMR. The AUC revealed that ITGB1, ITGB5, and OSMR played pivotal effects on the diagnosis of PAAD (Fig. 6A-C, P < 0.0001). Afterwards, the Oncomine datasets were utilized to verify the expression levels of these three key genes and discovered that compared with the pancreas tissues, the PAAD tumor tissues exhibited high expression levels of ITGB1, ITGB5, and OSMR (Fig. 6D-G, P < 0.05). Collectively, these observations showed that ITGB1, ITGB5, and OSMR could serve as important biomarkers for the prognosis and diagnosis of PAAD.

miRs that could target the key genes
To explore the potential molecular mechanism of these key genes, we firstly screened the DEmiRs in PAAD based on the TCGA database. After downloaded the miR-Seq expression profiles from TCGA database, the limma package of R software was applied to conduct difference analysis in accordance with the threshold (|logFC| > 1 and FDR < 0.05) and a total of 17 DEmiRs were obtained including 2 up-regulated miRs and 15 down-regulated miRs. Then, the miRs that have potential interactions with ITGB1, ITGB5, and OSMR were predicted using TargetScan website. The predicted miRs of these three key genes and DEmiRs that were decreased in PAAD were intersected, whose results indicated that ITGB1 and ITGB5 had a common regulatory miR, namely miR-16. Therefore, we speculated that miR-16, functioned as a crucial factor, might inhibit the progression of PAAD by mediating the
ITGB1/ITGB5/PI3K/Akt signaling pathway. To further validate the hypothesis, we subsequently detected the expression level of miR-16 in PAAD tissues and found that miR-16 expression was significantly declined in PAAD tissue samples compared with normal controls (Fig. 7A, P < 0.0001). Figure 7B suggested that miR-16 was positively correlated with survival rates of PAAD patients (P < 0.05). In summary, these findings demonstrated that miR-16 might affect the development of PAAD via regulating key genes ITGB1/ITGB5.

Screening of related small molecule drugs
In order to screen out the candidate small molecule drugs of PAAD, CMap was implemented on the basis of the analysis of consistent differently expressed probesets between PAAD tumor samples and normal specimens. The 29 related small molecule drugs with highly significant correlations were filtered by P < 0.01 and listed in Table 1. Among these small molecule drugs, thapsigargin, viomycin, adiphenine, and CP-690334-01 revealed higher obviously negative correlations and the potential to reverse the PAAD tumor status.
Table 1
Results of CMap analysis.

| cmap name     | mean  | n   | enrichment | p         | specificity | percent non-null |
|--------------|-------|-----|-----------|-----------|-------------|-----------------|
| thapsigargin | -0.857| 3   | -0.99     | 0         | 0.0065      | 100             |
| trichostatin A | 0.291 | 182 | 0.349     | 0         | 0.5924      | 51              |
| 8-azaquamine  | 0.75  | 4   | 0.891     | 0.00014   | 0.0296      | 100             |
| viomycin      | -0.633| 4   | -0.87     | 0.00058   | 0.0504      | 100             |
| mepacrine     | 0.792 | 2   | 0.979     | 0.00074   | 0.0052      | 100             |
| PHA-00745360  | -0.272| 8   | -0.649    | 0.00086   | 0.0078      | 50              |
| thiamphenicol | -0.435| 5   | -0.781    | 0.0009    | 0.0333      | 80              |
| emetine       | -0.495| 4   | -0.851    | 0.00093   | 0.0588      | 100             |
| Prestwick-692 | -0.567| 4   | -0.845    | 0.00103   | 0.0068      | 100             |
| heptaminol    | -0.32 | 5   | -0.773    | 0.00106   | 0.0137      | 60              |
| proscillaridin| 0.745 | 3   | 0.92      | 0.00112   | 0.0545      | 100             |
| genistein     | -0.351| 17  | -0.454    | 0.00114   | 0.0929      | 58              |
| bisacodyl     | 0.681 | 4   | 0.826     | 0.00143   | 0.0053      | 100             |
| indoprofen    | -0.488| 4   | -0.828    | 0.00165   | 0.02        | 100             |
| cephaeline    | -0.498| 5   | -0.75     | 0.00182   | 0.1325      | 80              |
| monensin      | -0.483| 6   | -0.693    | 0.00201   | 0.0894      | 83              |
| etiocholanolone | -0.306| 6   | -0.689    | 0.00219   | 0.0779      | 66              |
| pargyline     | 0.574 | 4   | 0.815     | 0.00223   | 0.0158      | 100             |
| bepridil      | 0.554 | 4   | 0.812     | 0.00237   | 0.0389      | 100             |
| felbinac      | -0.33 | 4   | -0.81     | 0.00257   | 0.0426      | 75              |
| adipheneine   | -0.601| 5   | -0.734    | 0.00274   | 0.1613      | 80              |
| canadine      | -0.319| 4   | -0.8      | 0.0031    | 0.0201      | 50              |
| trazodone     | 0.706 | 3   | 0.878     | 0.00349   | 0.0373      | 100             |
| 6-bromoindirubin-3'-oxime | -0.383| 7   | -0.626    | 0.00355   | 0.0794      | 71              |
| nadolol       | -0.34 | 4   | -0.783    | 0.00442   | 0.0769      | 50              |
| valproic acid | 0.235 | 57  | 0.229     | 0.00447   | 0.1908      | 54              |
| albendazole   | 0.655 | 3   | 0.851     | 0.00615   | 0.0058      | 100             |
| pheneticillin | -0.349| 4   | -0.759    | 0.00692   | 0.0131      | 75              |
| CP-690334-01 | -0.436| 8   | -0.552    | 0.00794   | 0.0816      | 62              |

P < 0.01. Bold fonts represent small molecule drugs with higher negative correlation and the potential to treat PAAD.

Discussion

PAAD is a highly aggressive tumor with dismal prognoses which is resulted by the lack of reliable biomarkers and therapeutic targets[1]. In our exploration, we conducted comprehensive bioinformatics analyses to identify key genes related with the progression of PAAD and finally found three key genes as well as several potential small molecule drugs to treat PAAD.

The three key genes OSMR, ITGB1, and ITGB5 play promoting effects on the progression of PAAD, and their high expression could induce poor prognoses in PAAD patients. These three genes have not been identified as crucial targets in PAAD. OSMR gene is located in chromosome 5p13.1 and encodes an important protein OSMRβ, which can be heterodimerized with IL-6 and then forming the type II OSMR[15]. It has been reported that type II OSMR was correlated with cell viability, differentiation, inflammatory responses and metastasis[16]. The association between the polymorphism of OSMR
gene and bladder cancer was determined, which would affect the recurrence rate, overall survival and tumor grade[17]. Xu et al. have discovered that OSMR might be a prognostic biomarker in glioblastoma and overexpression of OSMR can regulate the immune response of glioblastoma[18, 19]. Integrins are heterodimeric cell surface receptors composed of 18 α-subunits and 8 β-subunits, and modulate a variety of biological functions in tumorigenesis[20]. As previously described, ITGB1 is considered as a key adhesion receptor for ECM components and can contribute to cell proliferation, invasion and metastasis in various cancers[21, 22]. High-regulation of ITGB1 can stimulate the proliferation, invasion and migration in colorectal cancer cells[23]. ITGB1 is crucial for fascin-mediated breast cancer stem cell function and disease progression[24]. Lin et al. demonstrated that miR-185/ITGB5 played an essential role in the development of HCC through mediating β-catenin pathway[25]. In breast cancer cells, the tumorigenic ability could be facilitated due to the ITGB5-mediated EMT induced by transforming growth factor β[26]. Wortzel et al. found that ITGB5 was enriched in the exosomes of liver metastatic pancreatic carcinoma[27]. To further validate our results, we utilized ROC analysis and Oncomine datasets to detect their diagnostic significances and the expression levels in PAAD. All data showed that ITGB1, ITGB5, and OSMR had significant diagnostic potentials in PAAD, and all were remarkably increased in PAAD tissue samples compared with normal controls. These findings suggested that ITGB1, ITGB5, and OSMR might serve as important prognostic and diagnostic biomarkers in PAAD.

In order to explore how three key genes are regulated in PAAD, we used miR-Seq profiles from TCGA database to identify the DEmiRs, and a total of 2 up-regulated miRs and 15 down-regulated miRs were screened out. Then, integrated the above miRs with the upstream miRs of ITGB1, ITGB5, and OSMR predicted by TargetScan website, miR-16 was selected due to it is the common regulator of ITGB1 and ITGB5. Previous researches have indicated that miR-16 was involved in a variety of tumors, including cervical cancer[28], bladder cancer[29], and lung cancer[30]. Our results revealed that miR-16 was significantly decreased in PAAD tissues and patients with low miR-16 expression had poor outcomes. Therefore, we speculated that miR-16 might inhibit the invasion and metastasis of PAAD through regulating ITGB1/ITGB5-mediated PI3K-Akt pathway. Furthermore, miR-16 has been indicated
as a potential diagnostic target involved in the development of PAAD[31]. Therefore, further investigation of miR-16/ITGB1/ITGB5 axis in PAAD may be of great importance.

CMap is an useful tool for identifying the correlation between small molecule drugs and diseases based on the gene expression profiles[32]. To identify small molecule drugs with potential roles to treat PAAD, we conducted CMap analysis and observed that thapsigargin, viomycin, adiphenine, and CP-690334-01 may have potential therapeutic efficacy against PAAD. Among these, thapsigargin and adiphenine have been proven to posses anti-cancer effects while the role of the other two small drugs has not been studied. Thapsigargin is considered as an endoplasmic- reticulum Ca(2+)/ATPase pump inhibitor and correlated with the activation of NF-kappaB translocation in pancreatic cancer[33]. Moreover, thapsigargin can directly induce ER stress and decline the stemness[34]. Adiphenine has been widely used in clinical practice of local anesthetics and it has been reported as an adjuvant small drug to against ovarian cancer[35]. Therefore, we speculated that these identified small molecule drugs might have potential to treat PAAD.

However, there are some limitations in our present study. First, the effects of identified key genes on the phenotype of PAAD are insufficient and the possible molecular mechanism also needs to be further verified in the future. Second, this was only a retrospective investigation based on the public available databases, further in vivo and in vitro experiments should be performed to confirm our current results.

**Conclusion**

In summary, this present study identified three key genes linked with prognosis and diagnosis of PAAD, and four candidate small molecule drugs that posed the potential to reverse the tumor status of PAAD. These results may provide novel therapeutic targets and contribute to better prognosis of PAAD patients in the future.

**Abbreviations**

PAAD, pancreatic adenocarcinoma; WGCNA, weighted co-expression network analysis; CMap, Connectivity Map; DEGs, differentially expressed genes; GTEx, Genotype-Tissue Expression; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes

**Declarations**
Acknowledgments

None.

Authors’ contributions

YJ and YL designed the study. YJ, WP, and YL carried out bioinformatics analyses. YJ and WP wrote the manuscript. YL revised this manuscript. All authors read and approved the final manuscript.

Funding

None.

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article.

Competing interests

The authors declare that they have no competing interests.

Ethics Approval and consent to participate

Not applicable.

Consent for Publication

Not applicable.

Author details

1Department of pharmacy, Shandong Provincial Hospital, Jinan, 250022, Shandong P.R., China.

2Department of pharmacy, The first affiliated hospital of Shandong first medical university, Jinan, 250014, Shandong P.R., China.

References

1. Ma Y, Pu Y, Peng L, Luo X, Xu J, Peng Y, Tang X. Identification of potential hub genes associated with the pathogenesis and prognosis of pancreatic duct adenocarcinoma using bioinformatics meta-analysis of multi-platform datasets. Oncol Lett. 2019;18(6):6741-6751.

2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.

3. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371(11):1039-1049.

4. Cooperman AM, Bruckner H, Snady H, Hammerman H, Fader A, Feld M, Golier F, Rush T, Siegal J, Kasmin F, Cohen S, Wayne MG, Iskandar ME, Steele JG. Cancer of the Pancreas-Actual 5, 10, and 20+ Year Survival: The Lucky and Fortunate Few. Surg Clin North Am. 2018;98(1):73-85.

5. Brancaccio M, Natale F. Cell-Free DNA Methylation: The New Frontiers of Pancreatic Cancer Biomarkers' Discovery. 2019;11(1).

6. Wu M, Li X, Zhang T, Liu Z, Zhao Y. Identification of a Nine-Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival of Pancreatic Cancer. Front Oncol. 2019;9:996.

7. Wu J, Li Z, Zeng K, Wu K, Xu D, Zhou J, Xu L. Key genes associated with pancreatic cancer and their association with outcomes: A bioinformatics analysis. Mol Med Rep. 2019;20(2):1343-1352.

8. Zhang J, Wu Y, Jin HY, Guo S, Dong Z, Zheng ZC, Wang Y, Zhao Y. Prognostic value of sorting nexin 10 weak expression in stomach adenocarcinoma revealed by weighted gene co-expression network analysis. World J Gastroenterol. 2018;24(43):4906-4919.

9. Luo Y, Shen D, Chen L, Wang G, Liu X, Qian K, Xiao Y, Wang X, Ju L. Identification of 9 key genes and small molecule drugs in clear cell renal cell carcinoma. Aging (Albany NY). 2019;11(16):6029-6052.

10. Niemira M, Collin F, Szalkowska A, Bielska A, Chwialkowska K, Reszec J, Niklinski J, Kwasniewski M, Kretowski A. Molecular Signature of Subtypes of Non-Small-Cell Lung Cancer by Large-Scale Transcriptional Profiling: Identification of Key Modules and Genes by Weighted Gene Co-Expression Network Analysis (WGCNA). Cancers (Basel).
11. Su Q, Zhu EC, Qu YL, Wang DY, Qu WW, Zhang CG, Wu T, Gao ZH. Serum level of co-expressed hub miRNAs as diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma. J Cancer. 2018;9(21):3991-3999.

12. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.

13. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.

14. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929-1935.

15. Arita K, South AP, Hans-Filho G, Sakuma TH, Lai-Cheong J, Clements S, Odashiro M, Odashiro DN, Hans-Neto G, Hans NR, Holder MV, Bhogal BS, Hartshorne ST, Akiyama M, Shimizu H, McGrath JA. Oncostatin M receptor-beta mutations underlie familial primary localized cutaneous amyloidosis. Am J Hum Genet. 2008;82(1):73-80.

16. Isozaki O, Tsushima T, Miyakawa M, Emoto N, Demura H, Arai M, Sato-Nozoe Y. Oncostatin M: a new potent inhibitor of iodine metabolism inhibits thyroid peroxidase gene expression but not DNA synthesis in porcine thyroid cells in culture. Thyroid. 1997;7(1):71-77.

17. Deng S, He SY, Zhao P, Zhang P. The role of oncostatin M receptor gene polymorphisms in bladder cancer. World J Surg Oncol. 2019;17(1):30.

18. Xu P, Yang J, Liu J, Yang X, Liao J, Yuan F, Xu Y, Liu B, Chen Q. Identification of
glioblastoma gene prognosis modules based on weighted gene co-expression network analysis. BMC Med Genomics. 2018;11(1):96.

19. Guo Q, Guan GF, Cao JY, Zou CY, Zhu C, Cheng W, Xu XY, Lin ZG, Cheng P. Overexpression of oncostatin M receptor regulates local immune response in glioblastoma. 2019.

20. Lin Z, He R, Luo H, Lu C, Ning Z, Wu Y, Han C, Tan G, Wang Z. Integrin-β5, a miR-185-targeted gene, promotes hepatocellular carcinoma tumorigenesis by regulating β-catenin stability. J Exp Clin Cancer Res. 2018;37(1):17.

21. Xu Z, Zou L, Ma G, Wu X, Huang F, Feng T, Li S, Lin Q, He X, Liu Z, Cao X. Integrin β1 is a critical effector in promoting metastasis and chemo-resistance of esophageal squamous cell carcinoma. Am J Cancer Res. 2017;7(3):531-542.

22. Zhang J, Liu K, Peng P, Li S, Ye Z, Su Y, Liu S, Qin M, Huang J. Upregulation of nectin-4 is associated with ITGB1 and vasculogenic mimicry and may serve as a predictor of poor prognosis in colorectal cancer. Oncol Lett. 2019;18(2):1163-1170.

23. Ha YJ, Tak KH, Kim SK, Kim CW, Lee JL, Roh SA, Cho DH, Kim SY, Kim YS. Biological Characteristics and Clinical Significance of ITGB1 and RHOC in Patients With Recurrent Colorectal Cancer. 2019;39(9):4853-4864.

24. Barnawi R, Al-Khaldi S, Colak D, Tulbah A, Al-Tweigeri T, Fallatah M, Monies D, Ghebeh H. β1 Integrin is essential for fascin-mediated breast cancer stem cell function and disease progression. 2019;145(3):830-841.

25. Lin Z, He R, Luo H, Lu C, Ning Z, Wu Y, Han C, Tan G, Wang Z. Integrin-beta5, a miR-185-targeted gene, promotes hepatocellular carcinoma tumorigenesis by regulating beta-catenin stability. J Exp Clin Cancer Res. 2018;37(1):17.

26. Bianchi A, Gervasi ME, Bakin A. Role of β5-integrin in epithelial-mesenchymal transition in response to TGF-beta. Cell Cycle. 2010;9(8):1647-1659.
27. Wortzel I, Dror S, Kenific CM, Lyden D. Exosome-Mediated Metastasis: Communication from a Distance. Dev Cell. 2019;49(3):347-360.

28. Zhang S, Wang W, Wu X, Liu W, Ding F. miR-16-5p modulates the radiosensitivity of cervical cancer cells via regulating coactivator-associated arginine methyltransferase 1. 2019.

29. Yang R, Xu J, Hua X, Tian Z, Xie Q, Li J, Jiang G, Cohen M, Sun H, Huang C. Overexpressed miR-200a promotes bladder cancer invasion through direct regulating Dicer/miR-16/JNK2/MMP-2 axis. Oncogene. 2019.

30. Zhou X, Xu X, Gao C, Cui Y. XIST promote the proliferation and migration of non-small cell lung cancer cells via sponging miR-16 and regulating CDK8 expression. Am J Transl Res. 2019;11(9):6196-6206.

31. Johansen JS, Calatayud D, Albieri V, Schultz NA, Dehlendorff C, Werner J, Jensen BV, Pfeiffer P, Bojesen SE, Giese N, Nielsen KR, Nielsen SE, Yilmaz M, Hollander NH, Andersen KK. The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer. Int J Cancer. 2016;139(10):2312-2324.

32. Yoo M, Shin J, Kim H, Kim J, Kang J, Tan AC. Exploring the molecular mechanisms of Traditional Chinese Medicine components using gene expression signatures and connectivity map. Comput Methods Programs Biomed. 2019;174:33-40.

33. Arita Y, Ito T, Oono T, Kawabe K, Hisano T, Takayanagi R. Lysophosphatidic acid induced nuclear translocation of nuclear factor-kappaB in Panc-1 cells by mobilizing cytosolic free calcium. World J Gastroenterol. 2008;14(28):4473-4479.

34. Tadros S, Shukla SK, King RJ, Gunda V, Vernucci E, Abrego J, Chaika NV, Yu F, Lazenby AJ, Berim L, Grem J, Sasson AR, Singh PK. De Novo Lipid Synthesis Facilitates Gemcitabine Resistance through Endoplasmic Reticulum Stress in Pancreatic Cancer. Cancer Res. 2017;77(20):5503-5517.
35. Sun N, Zang W, Li W. Bioinformatics analysis reveals potential candidate drugs for psychological stress in ovarian cancer. Eur Rev Med Pharmacol Sci. 2012;16(10):1362-1366.

Figures
Identification of DEGs in PAAD based on the TCGA and GTEx datasets. Volcano plot of gene expression profile data between PAAD and normal samples. Red dots represent upregulated genes in PAAD; green dots represents down-regulated genes; black dots represents non-differentially expressed genes. $|\log FC| > 1$, FDR $< 0.05$. DEGs, differentially expression genes; PAAD, pancreatic adenocarcinoma; TCGA, the Cancer Genome Atlas; GTEx, Genotype-Tissue Expression.
Figure 2

Weighted co-expression network establishment. The cluster dendrogram of the DEGs; each branch represents one gene and the co-expression modules are represented by different colors. DEGs, differentially expression genes.
Figure 3
Interaction relationship among modules and identification of pivotal modules. (A) Interaction relationship analysis of co-expression genes. Different colors of horizontal axis and vertical axis represent different modules. The brightness of yellow in the middle represents the degree of connectivity of different modules. (B-G) Scatter plots of module eigengenes in corresponding modules that correlated with clinical features.
Figure 4

Enrichment analyses of blue module. (A) Go enrichment analysis and (B) KEGG pathway analysis of all genes in blue module. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.
Identification of key genes in PAAD. (A-C) Overall survival curves of three key genes in PAAD. (D-F) Disease free survival analyses of three key genes in PAAD. (G-I) Expression levels of ITGB1, ITGB5, and OSMR in PAAD tissues and normal tissue samples. PAAD, pancreatic adenocarcinoma.
Figure 6

Diagnostic significance of three key genes and validation of the expression levels of key genes. (A-C) ROC curves and AUC were utilized to evaluate the specificity and sensitivity of key genes on PAAD diagnosis. (D-G) Data from Oncomine datasets confirmed that ITGB1, ITGB5, and OSMR were significantly increased in PAAD tissues compared with normal controls. ROC, Receiver operating characteristic; AUC, area under the curve; PAAD, pancreatic adenocarcinoma.
MiR-16 expression was dramatically decreased in PAAD and positively correlated with prognosis of PAAD patients. (A) Expression level of miR-16 between PAAD tissue samples and normal pancreatic tissues. (B) Overall survival curve of miR-16 in PAAD patients was plotted using Kaplan-Meier analysis. PAAD, pancreatic adenocarcinoma.